Tudor Investment Corp ET AL Grows Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Tudor Investment Corp ET AL grew its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 295.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 585,865 shares of the medical technology company's stock after buying an additional 437,690 shares during the period. Tudor Investment Corp ET AL owned 0.41% of Alphatec worth $5,378,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ATEC. R Squared Ltd purchased a new position in Alphatec in the fourth quarter worth $29,000. Nisa Investment Advisors LLC grew its stake in Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after buying an additional 4,234 shares during the last quarter. Quarry LP increased its position in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after buying an additional 2,375 shares in the last quarter. Newton One Investments LLC purchased a new stake in Alphatec in the fourth quarter valued at about $50,000. Finally, AlphaQuest LLC acquired a new stake in Alphatec in the fourth quarter worth about $80,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Insider Transactions at Alphatec

In related news, CEO Patrick Miles sold 43,459 shares of Alphatec stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total value of $519,335.05. Following the sale, the chief executive officer now owns 6,065,772 shares of the company's stock, valued at approximately $72,485,975.40. This trade represents a 0.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Sponsel sold 33,732 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the completion of the sale, the executive vice president now directly owns 668,977 shares of the company's stock, valued at approximately $7,245,020.91. The trade was a 4.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 185,857 shares of company stock valued at $2,105,682 in the last ninety days. 22.80% of the stock is currently owned by corporate insiders.

Alphatec Stock Performance

ATEC stock traded down $0.02 during trading on Tuesday, hitting $11.97. 355,864 shares of the company traded hands, compared to its average volume of 2,069,434. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $13.79. The stock's 50-day simple moving average is $10.48 and its 200 day simple moving average is $9.96. The company has a market cap of $1.75 billion, a PE ratio of -9.35 and a beta of 1.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business's revenue for the quarter was up 22.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on ATEC shares. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday. Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Alphatec in a report on Friday. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Barclays lifted their price target on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.